Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nab-sirolimus,Sotorasib,Adagrasib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ABI-009 (Nab-sirolimus) is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Brand Name : ABI-009
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2022
Lead Product(s) : Nab-sirolimus,Sotorasib,Adagrasib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Adagrasib,Nab-sirolimus
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Mirati Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the terms of the collaboration agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study of Adagrasib (MRTX849), and jointly with Aadi, will oversee and share the cost of the study.
Brand Name : MRTX849
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 12, 2022
Lead Product(s) : Adagrasib,Nab-sirolimus
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Mirati Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
Details : The company intends to use net proceeds from the financing to fund research and development of Nab-sirolimus and additional clinical opportunities with FYARRO and for working capital and general corporate purposes.
Brand Name : Fyarro
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 22, 2022
Details : Nab-sirolimus is an albumin-bound mTOR inhibitor approved by the U.S. Food and Drug Administration (FDA) as FYARRO™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa.
Brand Name : Fyarro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 26, 2022
Lead Product(s) : Nab-sirolimus
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Foundation Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Details : Partners will collect and analyze clinical and molecular data to determine which patients may be eligible to participate in Aadi’s PRECISION 1 clinical trial for ABI-009. The goals are to increase patient match rate, reduce screen failure rate and incr...
Brand Name : ABI-009
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Nab-sirolimus
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Foundation Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Based on data from the AMPECT trial with FYARRO and following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a tumor-agnostic registrational trial in mTOR inhibitor-naïve solid tumors.
Brand Name : Fyarro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 08, 2022
Details : FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Brand Name : Fyarro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2022
Details : nab-Sirolimus (ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors.
Brand Name : Fyarro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2021
Lead Product(s) : Nab-sirolimus
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Aerpio Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
Details : The combined, publicly traded company will focus on the advancement, expansion and commercialization of Aadi’s clinical stage pipeline, including Aadi’s lead program for its nanoparticle albumin-bound mTOR inhibitor, FYARRO™, an mTOR inhibitor boun...
Brand Name : Fyarro
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 26, 2021
Lead Product(s) : Nab-sirolimus
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Aerpio Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
Details : Proceeds from the PIPE financing are expected to be used for the commercialization of FYARRO in advanced malignant PEComa, a planned tumor-agnostic registrational trial in solid tumors harboring inactivating alterations in the mTOR pathway genes TSC1 and...
Brand Name : Fyarro
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 26, 2021
LOOKING FOR A SUPPLIER?